A spore-forming probiotic that survives stomach acid and supports digestive and immune health. Survives stomach acid as a spore, then activates in your gut to support digestion and crowd out harmful bacteria
Reviewed March 2026
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
A pairing appears on this page only when a trial gave both ingredients together and measured the result. Bacillus Licheniformis has none that clears that bar.
Stitching two separate single-ingredient studies into a pairing is the one thing this engine will not do. When a study of the combination itself holds up at source, it lands here with its citation.
No invented synergy. Where actives were studied on their own rather than together, the record shows each on its own evidence, never a combined effect no trial measured.
Research strength. Research strength says how much work stands behind the combination. It is never a product score.
Independent record. Every finding is cited to a named trial, dated, and never written by the brand.
20 pairings are live across the library today. Checked 20 July 2026.
No study gave these as a pair, so they are not in the card above. But the reason they belong together is settled biochemistry, not a guess, so it is worth knowing.
Bacillus licheniformis has been paired with lactic acid strains in combination products for decades because its spores clear gastric acid intact and germinate to consume oxygen, which suits the strictly fermentative strains alongside it.
Spore formers survive manufacture, shelf storage and gastric transit far better than vegetative strains, so they are added to multi-strain blends to hold total delivered count.
Bacillus licheniformis secretes alpha-amylase, the enzyme industry sources from it, so the strain adds starch-hydrolysing activity of the same class as a supplemental amylase.
The species secretes alkaline proteases and amylases into the lumen, adding to a formulated enzyme blend rather than repeating one activity.
Germinated cells need fermentable carbohydrate to establish, and inulin carries fructans into the colon where they are broken down to short-chain fatty acids.
Carvacrol-rich oils act on bacterial membranes indiscriminately, lowering viable counts of a co-formulated strain once its spores germinate.
Charcoal adsorbs luminal organic matter broadly, including substrate and metabolites the strain relies on, so the two are separated by several hours.
Clay platelets bind bacterial cells and organic material as they transit, which can carry a co-dosed strain through with them.
Both are transient organisms that pass through the gut rather than settling permanently, and they occupy different niches: one is a spore-forming bacterium, the other a yeast unaffected by antibacterial agents. Formulators combine them so that a single product keeps some transient activity across a wider set of gut conditions. The pairing is a formulation rationale drawn from what each organism is known to tolerate, not a measured combination effect in people.
Bacillus licheniformis arrives as a dormant spore and germinates in the small intestine, while Bifidobacterium longum is a resident-type anaerobe of the colon. Organic acids released by Bacillus fermentation lower luminal pH, conditions that bifidobacteria tolerate well. The combination is standard multi-strain practice; the division of niches is established, the joint effect on any human outcome is not established here.
Spore-formers and bifidobacteria are frequently blended because their vulnerabilities differ: the spore coat carries Bacillus through gastric acid, whereas Bifidobacterium lactis is comparatively oxygen and acid tolerant for its genus. Nothing in the pairing requires one organism to metabolise the other's products. Read this as a compatible blend rather than a demonstrated combination benefit.
Lactobacillus plantarum is a lactic acid producer and Bacillus licheniformis secretes extracellular amylases and proteases that release simpler sugars and peptides from the food matrix. That substrate release is the mechanistic link most often given for pairing the two. The enzymology is established; the downstream benefit of combining them in humans is not.
The two species are the usual pair in spore-based blends and both germinate in the upper small intestine, so they draw on overlapping niches and substrates. A poultry study reported that fermented products from the two species did not act identically on growth and intestinal measures, which argues against regarding them as interchangeable. That work was in birds, so it grounds the distinction in mechanism, not a human effect.
A fish study tested dietary Spirulina platensis and Bacillus licheniformis individually and together and reported effects on growth and immune measures. This is the only genuine combination record available for the pairing and it was run in a non-human species. It supports a plausible additive rationale and nothing more.
FOS is not digested by human enzymes and reaches the colon intact, where it is fermented to short-chain fatty acids by resident bacteria. Bacillus licheniformis contributes its own carbohydrate-degrading enzymes to the same lumen. The substrate chemistry is settled; which organisms gain most from it in a given gut is not fixed.
Bacillus licheniformis is an industrial source of heat-stable alpha-amylase, and resistant starch is by definition starch that escapes host amylase. Bacterial amylases can act on starch fractions the host leaves behind, releasing fermentable sugars in the lumen. The enzyme chemistry is well established; whether that changes a measurable human outcome has not been shown here.
Partially hydrolysed guar gum is a low-viscosity soluble fibre fermented in the colon, so it is easy to co-formulate with a spore preparation without thickening the product. The fibre supports normal stool form and supplies fermentation substrate. The combination is a formulation choice grounded in fibre chemistry.
Psyllium forms a gel that holds water and slows transit, only partly fermented by gut bacteria. Slower transit lengthens the window in which a germinated Bacillus population sits in the small intestine. That is a plausible mechanical interaction rather than a measured one, and the gel can also entrap co-ingested material.
Oat beta-glucan is a viscous soluble fibre fermented to short-chain fatty acids in the colon. Bacillus species carry glucanase activity, so part of the polymer can be broken down before resident fermenters reach it. Established enzymology, unmeasured joint effect.
Butyrate is the main energy source for colonocytes and the usual end product of fibre fermentation. Supplying it directly and supplying a fermenting organism converge on the same luminal chemistry from two directions. The metabolism is textbook; the additive framing is mechanistic rather than an outcome measured for this combination.
Bovine colostrum carries immunoglobulins and oligosaccharides that bind bacterial surfaces, which is why it is sometimes paired with live organisms. Those same binding properties are non-selective, so an interaction with a supplied organism can run either way. No combination data grounds a direction, so keep this as a mechanistic note.
Lactoferrin binds free iron tightly, and iron restriction slows the growth of many bacteria that need it. Some genera are relatively iron-independent and others are not, so co-dosing a strong iron binder with a live organism is worth flagging rather than assuming it helps. The chelation chemistry is established; the effect on a given Bacillus preparation has not been measured.
Berberine has broad antibacterial activity in vitro and reaches the gut lumen at high local concentrations because systemic absorption is poor. A germinated, vegetative Bacillus population is exposed to that activity; the dormant spore is far less so. Spacing the two is the practical inference from the pharmacology, not from a combination trial.
Crushed garlic generates thiosulfinates with broad antibacterial activity in the gut lumen. That activity does not distinguish a supplied organism from a resident one. Established chemistry, direction of net effect on a spore product unmeasured.
Thymol and carvacrol disrupt bacterial membranes, which is why thyme oil is used as a feed antimicrobial. Dormant endospores are far more resistant to these compounds than vegetative cells, so timing matters more than exclusion. The membrane chemistry is established; no combination study grounds an amount.
Betaine HCl lowers gastric pH, the condition most vegetative probiotic organisms do not survive. Bacillus endospores are structurally resistant to acid, which is the basis of the page's stored claim that the organism survives stomach acid. Co-dosing is therefore compatible in mechanism; it has not been measured as a benefit.
Zinc is required for normal epithelial turnover and tight-junction protein expression, so it supports the same barrier that gut organisms sit against. The two act through unrelated routes rather than one enabling the other. This is a mechanistic pairing at low confidence and no combination evidence.
Talk to a doctor before taking Bacillus Licheniformis if any of these apply to you: Less studied than other Bacillus species, Some strains produce toxins (strain matters), Immunocompromised people should be cautious. These are flags to check first, not effects Bacillus Licheniformis is known to cause.
Not medical advice. Show the label to your pharmacist.The whole-food sources on file. A supplement closes the gap, it does not replace dinner.
A gram-for-gram figure (how much of each you would eat to match a dose) will appear here once it is sourced and reviewed. This page will not print a number it cannot cite.
These are the studies our verdict leans on, chosen from the 13 we read for Bacillus Licheniformis. The full linked list is below.
3 sources behind our Bacillus Licheniformis verdict: peer-reviewed studies and registered clinical trials. Every one links straight to PubMed, the journal, or ClinicalTrials.gov. Read them yourself.
Evidence surfaced via Semantic Scholar (Allen Institute for AI) and ClinicalTrials.gov. Ranked by study type and citation weight, not cherry-picked.
Read this carefully. These are 181 voluntary, unverified reactions reported to the FDA (openFDA). The number mostly reflects how popular Bacillus Licheniformis is, not how risky it is. A report is not proof Bacillus Licheniformis caused anything. It is a signal of what to watch for, nothing more.
Source: openFDA adverse-event reports. Voluntary reporting, not an incidence rate.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.